X0306 4 2020-12-11 0 0001703057 AbCellera Biologics Inc. ABCL 0001198174 HAMER JOHN C/O ABCELLERA BIOLOGICS INC. 2215 YUKON STREET VANCOUVER A1 V5Y 0A1 BRITISH COLUMBIA, CANADA 1 0 1 0 Common Shares 2020-12-15 4 C 0 29076350 A 29076350 I See footnote Common Shares 2020-12-15 4 C 0 29411 A 29105761 I See footnote Convertible Note 2020-12-11 4 A 0 500000.00 500000.00 A Common Shares 29411 500000.00 I See footnote Series A1 Preferred Shares 2020-12-15 4 C 0 2105264 0.00 D Common Shares 21052640 0 I See footnote Series A2 Preferred Shares 2020-12-15 4 C 0 802371 0.00 D Common Shares 8023710 0 I See footnote Convertible Note 17.00 2020-12-15 4 C 0 500000.00 0.00 D Common Shares 29411 0 I See footnote These securities are held by DCVC Bio, L.P. ("DCVC Bio"). DCVC Bio GP, LLC ("DCVC Bio GP") is the general partner of DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP. JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person is one of the managing members of JNK. The managing members of JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that he is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any, by virtue of his interest in DCVC Bio GP and JNK, as applicable. The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date. The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share. This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. Remarks: This is one of two Form 4s filed on the date hereof in respect of these securities. The Reporting Persons for the other Form 4 are DCVC Bio, DCVC Bio GP, JNK, ZNM, Matthew Ocko, Zachary Bogue and Kiersten Stead. /s/ Tryn Stimart, attorney-in-fact 2020-12-17